Cancer

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…

5 days ago

BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpointHighly expressed on the cell surfaces of…

5 days ago

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the…

5 days ago

Acurion Unveils Rebrand, New Leadership Team, and Series A Fundraising Launch

LA JOLLA, Calif., April 9, 2025 /PRNewswire/ -- Acurion, formerly known as io9, today announced its official rebranding as part…

6 days ago

Mercy Awarded Funding to Expand AI-driven Smart-Texting Program

ST. LOUIS, April 9, 2025 /PRNewswire/ -- Mercy has been approved for a four-year funding award from the Patient-Centered Outcomes…

6 days ago

Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation

- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 — a full automation system expected to cover the entire…

6 days ago

Cepheid and Oxford Nanopore Technologies Partner to Advance Automated Sequencing-Based Solutions

Collaboration to leverage Oxford Nanopore's sequencing platform and Cepheid's GeneXpert system to advance the field of sequencing for infectious diseases…

6 days ago

Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System

Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY® showed a 92% reduction…

6 days ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody…

6 days ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect…

6 days ago